

JUL 01 2004

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
704-444-1000
Fax: 704-444-1111

OFFICIAL**TELECOPY****PLEASE DELIVER AS SOON AS POSSIBLE****Date:**

July 1, 2004

Recipient:

Examiner Robert A. Wax

Company:U.S. PATENT & TRADEMARK
OFFICE**Fax Number:**

(703) 872-9306

Voice Number:**Sender:**

Raymond O. Linker, Jr.

Message:

Application No. 09/254,032

OFFICIAL AFTER FINAL RESPONSE

Number of Pages: (including cover page)

8

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT.

USER CODE:	LINKR	REQUESTED BY:	Jan Sherrill - 1163
CLIENT/MATTER:	033339/176332	OPERATOR:	

Alston & Bird

JUL 01 2004

OFFICIAL

PATENT

RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED
PROCEDURE - EXAMINING GROUP 1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 09/254,032 Confirmation No.: 6404
Applicant(s): Serre et al.
Filed: 04/26/1999
Art Unit: 1653
Examiner: Robert A. Wax
Title: ANTIGENS DERIVED FROM FILAGGRIN AND THEIR USE FOR
DIAGNOSING RHEUMATOID POLYARTHRITIS

Docket No.: 033339/176332
Customer No.: 00826

July 1, 2004

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL ACTION
PURSUANT TO 37 C.F.R. § 1.116

Sir:

In response to the final Office Action dated April 7, 2004, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims beginning on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.